Skip to main content

Table 1 Baseline characteristics: phase II part

From: A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer

  Xe1000+Ev10+Ex25 (n = 70) Ev10+Ex25 (n = 70) Total (n = 140)
Median age, years (range) 58.5 (41–86) 62.0 (42–84) 60.0 (41–86)
ECOG PS, n (%)
 0 45 (64.3) 38 (54.3) 83 (59.5)
 1 25 (35.7) 31 (44.3) 56 (40.0)
 2 0 1 (1.4) 1 (0.7)
Median time since diagnosis, months (range) 63.4 (12.4–343.5) 63.3 (8.3–256.6) 63.3 (8.3–343.5)
Metastatic sites at screening, n (%)
 1 18 (25.7) 16 (22.9) 34 (24.3)
 2 25 (35.7) 27 (38.6) 52 (37.1)
 ≥ 3 27 (38.6) 27 (38.6) 54 (38.6)
Visceral involvement, n (%)
 Yes 53 (75.7) 54 (77.1) 107 (76.4)
 No 17 (24.3) 16 (22.9) 33 (23.6)
Bone metastases, n (%) 47 (67.1) 52 (74.3) 99 (70.7)
Lymph node metastases, n (%) 33 (47.1) 25 (35.7) 58 (41.4)
Prior hormone therapy, n (%) 68 (97.1) 69 (98.6) 137 (97.9)
Prior chemotherapy in metastatic setting, n (%) 17 (24.3) 18 (25.7) 35 (25.0)
Prior CDK 4/6 inhibitor treatment, n (%) 0 2 (2.9) 2 (1.4)
  1. CDK cyclin-dependent kinase, ECOG PS Eastern Cooperative Oncology Group performance status